Document:

EX-10.10

 Exhibit 10.10 

EMPLOYEE NONCOMPETITION, 

NONDISCLOSURE AND DEVELOPMENTS AGREEMENT 

This Employee Noncompetition, Nondisclosure and Developments Agreement (the “Agreement”) is entered into by and between the
undersigned employee and Rib-X Pharmaceuticals, Inc., its parents, affiliates and subsidiaries (the “Company”). 

WHEREAS, the Company is in negotiations with investors to obtain critical financing, which is necessary for the continued operation of the
Company; 
 WHEREAS, my execution of this Agreement is a condition of the investors’ provision of financing to the Company; 

WHEREAS, in the absence of such financing, my employment with the Company, and my salary and benefits as a consequence thereof, would cease;
and 
 WHEREAS, the Company agrees to provide me with two weeks’ notice prior to termination from employment and/or payment in lieu of
such notice; 
 NOW THEREFORE, in consideration of the covenants herein, my continued employment with the Company, the Company’s
provision of two weeks’ notice of termination, and for other good and valuable consideration, I hereby covenant and agree as follows: 

1. Best Efforts. During the period of my employment by the Company, I shall devote my full time and best efforts to the business of the
Company, and I shall neither pursue any business opportunity outside the Company nor take any position with any organization other than the Company without the written approval of the Chief Executive Officer or his/her designee. 

2. Noncompetition. During the period of my employment by the Company, I shall not, directly or indirectly, alone or as a consultant,
partner, officer, director, employee, joint venturer, lender or stockholder of any entity, engage in any business or activity that is in competition with the products or services being created, developed, manufactured, marketed, distributed or sold
by the Company in (a) the State of Connecticut, (b) the States of New York, Massachusetts and Connecticut, (c) the continental United States of America, (d) the United States and Europe or (e) worldwide. For one year following
the termination of my employment, regardless of the reasons for my termination, I will refrain from management of or participation in research programs at or on behalf of any entity in areas related to antimicrobials targeted to the Ribosome and in
areas related to specific chemical approaches or series the Company is engaged in during my employment or in which the Company is planning to engage. In the case of areas of business unrelated to antimicrobials, for one year following the
termination of my employment, regardless of the reasons for my termination, I will refrain from management of or participating in any such non-antimicrobial programs which are under prosecution at the company
or in which the Company is planning to engage 
 3. Nonsolicitation of Customers. During the period of my employment by the Company
and for one year following the termination of my employment, regardless of the reasons for my termination, I shall not, directly or indirectly, alone or as a consultant, partner, officer, director, employee, joint venturer, lender or stockholder of
any entity, solicit or do business with any customer of the Company or any potential customer of the Company (i) with whom I have had contact or (ii) about whom I obtained information, or became familiar with through Confidential
Information (as defined in Paragraph 5), during the course of my employment with the Company. 

 4. Nonsolicitation of Employees. 

(a) During the period of my employment by the Company and for one year following the termination of my employment, regardless of the reasons
for the termination, I will not, in any manner, hire or engage, or assist any company or business organization by which I am employed or which is directly or indirectly controlled by me to hire or engage, any person who is or was employed by the
Company (or is or was an agent, representative, contractor, project consultant or consultant of the Company) at the time of my termination. 

(b) During the period of my employment by the Company and for one year following the termination of my employment, regardless of the reasons
for the termination, I will not, in any manner, solicit, recruit or induce, or assist any company or business organization by which I am employed or which is directly or indirectly controlled by me to solicit, recruit or induce, any person who is or
was employed by the Company (or is or was an agent, representative, contractor, project consultant or consultant of the Company) at the time of my termination, to leave his or her employment, relationship or engagement with the Company. 

5. Nondisclosure. I shall not at any time, whether during or after the termination of my employment, reveal to any person or entity any
Confidential Information except to employees of the Company who need to know such Confidential Information for the purposes of their employment, or as otherwise authorized by the Company in writing. The term “Confidential Information”
shall include any information concerning the organization, business or finances of the Company or of any third party which the Company is under an obligation to keep confidential that is maintained by the Company as confidential. Such Confidential
Information shall include, but is not limited to, trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, specifications,
blueprints, engineering data, software programs, works of authorship, customer lists, customer information, financial information, pricing information, personnel information, business plans, projects, plans and proposals. I shall keep confidential
all matters entrusted to me and shall not use or attempt to use any Confidential Information except as may be required in the ordinary course of performing my duties as an employee of the Company, nor shall I use any Confidential Information in any
manner which may injure or cause loss or may be calculated to injure or cause loss to the Company, whether directly or indirectly. 
 6.
Assignment of Developments. 
 (a) If at any time or times during my employment, I shall (either alone or with others) make, conceive,
create, discover, invent or reduce to practice any Development that (i) relates to the business of the Company or any customer of or supplier to the Company or any of the products or services being developed, manufactured or sold by the Company
or which may be used in relation therewith; or (ii) results from tasks assigned to me by the Company; or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, 

  
 Erin Noncompete 1-8-02 
 -2- 

 
leased or contracted for by the Company, then all such Developments and the benefits thereof are and shall immediately become the sole and absolute property of the Company and its assigns, as
works made for hire or otherwise. The term “Development” shall mean any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how, trade secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright, trademark or similar statutes (including, but not limited to, the
Semiconductor Chip Protection Act) or subject to analogous protection). I shall promptly disclose to the Company (or any persons designated by it) each such Development. I hereby assign all rights (including, but not limited to, rights to
inventions, patentable subject matter, copyrights and trademarks) I may have or may acquire in the Developments and all benefits and/or rights resulting therefrom to the Company and its assigns without further compensation and shall communicate,
without cost or delay, and without disclosing to others the same, all available information relating thereto (with all necessary plans and models) to the Company. 

(b) Excluded Developments. I represent that the Developments identified in the Appendix, if any, attached hereto comprise all the
Developments that I have made or conceived prior to my employment by the Company, which Developments are excluded from this Agreement. I understand that it is only necessary to list the title of such Developments and the purpose thereof but not
details of the Development itself. IF THERE ARE ANY SUCH DEVELOPMENTS TO BE EXCLUDED, THE UNDERSIGNED SHOULD INITIAL HERE; OTHERWISE IT WILL BE DEEMED THAT THERE ARE NO SUCH EXCLUSIONS. /s/ EMD 

7. Further Assurances. I shall, during my employment and at any time thereafter, at the request and cost of the Company, promptly sign,
execute, make and do all such deeds, documents, acts and things as the Company and its duly authorized officers may reasonably require: 

(a) to apply for, obtain, register and vest in the name of the Company alone (unless the Company otherwise directs) patents,
copyrights, trademarks or other analogous protection in any country throughout the world relating to a Development and when so obtained or vested to renew and restore the same; and 

(b) to defend any judicial, opposition or other proceedings in respect of such applications and any judicial, opposition or
other proceeding, petition or application for revocation of any such patent, copyright, trademark or other analogous protection. 
 If the
Company is unable, after reasonable effort, to secure my signature on any application for patent, copyright, trademark or other analogous protection or other documents regarding any legal protection relating to a Development, whether because of my
physical or mental incapacity or for any other reason whatsoever, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and
attorney-in-fact, to act for and in my behalf and stead to execute and file any such application or applications or other documents and to do all other lawfully
permitted acts to further the prosecution and issuance of patent, copyright or trademark registrations or any other legal protection thereon with the same legal force and effect as if executed by me. 

  
 Erin Noncompete 1-8-02 
 -3- 

 8. Employment At Will. I understand that this Agreement does not constitute an implied or
written employment contract and that my employment with the Company is on an “at-will” basis. Accordingly, I understand that either the Company or I may terminate my employment at any time, for any
or no reason, with or without prior notice. 
 9. Severability. I hereby agree that each provision and the subparts of each provision
herein shall be treated as separate and independent clauses, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses of the Agreement. Moreover, if one or more of the provisions contained in
this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or
reducing it or them, so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear. I hereby further agree that the language of all parts of this Agreement shall in all cases be construed as a whole
according to its fair meaning and not strictly for or against either of the parties. 
 10. Amendments; Waiver. Any amendment to or
modification of this Agreement, or any waiver of any provision hereof, shall be in writing and signed by the Company. Any waiver by the Company of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any
subsequent breach of such provision or any other provision hereof. 
 11. Survival. This agreement shall be effective as of the date
entered below. My obligations under this Agreement shall survive the termination of my employment regardless of the manner of such termination and shall be binding upon my heirs, executors, administrators and legal representatives. 

12. Assignment. The Company shall have the right to assign this Agreement to its successors and assigns, and all covenants and
agreements hereunder shall inure to the benefit of and be enforceable by said successors or assigns. I may not assign this Agreement. 
 13.
Representations. 
 (a) I represent that my employment with the Company and my performance of all of the terms of this Agreement do
not and will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I shall not enter into, any agreement either written or
oral in conflict herewith. 
 (b) I agree that the restrictions set forth in paragraph 2 hereof are reasonable and necessary to protect
specific business interests of the Company. I agree that any breach of this Agreement by me will cause irreparable damage to the Company and that in the event of such breach the Company shall have, in addition to any and all remedies of law, the
right to an injunction, specific performance or other equitable relief to prevent the violation of my obligations hereunder. The Company may apply for such injunctive relief in any court of competent jurisdiction without the necessity of posting any
bond or other security. 

  
 Erin Noncompete 1-8-02 
 -4- 

 14. Governing Law; Forum Selection Clause. This Agreement and any claims arising out of
this Agreement (or any other claims arising out of the relationship between the parties) shall be governed by and construed in accordance with the laws of the State of Connecticut and shall in all respects be interpreted, enforced and governed under
the internal and domestic laws of such state, without giving effect to the principles of conflicts of laws of such state. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or federal court
located in such state, and I hereby submit to the jurisdiction and venue of any such court. 
 15. Entire Agreement. This Agreement
sets forth the complete, sole and entire agreement between the parties on the subject matter herein and supersedes any and all other agreements, negotiations, discussions, proposals, or understandings, whether oral or written, previously entered
into, discussed or considered by the parties. 
 IN WITNESS WHEREOF, the undersigned has executed this Agreement as a sealed instrument as
of the date first above written. 
  

			
	 /s/ Erin M. Duffy

	Signature
	
	 Erin M. Duffy

	Name (Please Print)
		
	Date:	 	01.09.2001
		
	Address:	 	349 River Road
		 	Deep River, CT 06417

  
 Erin Noncompete 1-8-02 
 -5-EX-10.11

 Exhibit 10.11 
  

 
 February 5, 2016 

John Temperato 
 President and Chief Operating Officer 

Melinta Therapeutics, Inc. 
 RE: Severance
Agreement 
 Dear John: 
 Effective as of
February 16, 2016, you will be a key member of the senior management team of Melinta Therapeutics, Inc. (the “Company”). As a result, the Company is providing you with the following benefits in consideration of your employment
with the Company. 
  

	I.	Definitions. For the purposes of this Severance Agreement (this “Agreement”), capitalized terms shall have the following meanings: 

 

	 	1.	“Cause” shall mean: 

  

	 	(a)	your conviction of or your plea of guilty to or confession of an act of fraud, misappropriation or embezzlement or any felony; 

  

	 	(b)	your willful refusal or failure to follow a lawful directive or instruction of the Company’s board of directors or the individual(s) to whom you report; 

 

	 	(c)	in carrying out your duties, you commit material dishonesty or you breach a fiduciary duty to the Company; 

  

	 	(d)	you engage in conduct which causes material injury to the Company, monetarily or otherwise; 

  

	 	(e)	you use illegal substances at any time; or 

  

	 	(f)	you materially breach any Company policies regarding confidentiality, insider trading, any employment agreement with the Company then in effect or your Employee Noncompetition, Nondisclosure and Developments Agreement.

  

	 	2.	“Change in Control” shall mean the date: 

  

	 	(a)	any “person” or “group” (as such terms are used in Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) is or becomes the beneficial owner of our securities representing
50% or more of the total voting power of the Company’s then-outstanding voting securities, pursuant to a transaction which the Company’s board of directors does not approve; 

 

	 	(b)	 the Company undergoes a merger, reorganization or other consolidation, including the sale of substantially all of
the Company’s assets, in which the Company is not the 

	 	
surviving entity and in which the persons holding the Company’s outstanding equity immediately prior to such merger, reorganization or consolidation own less than 50% of the surviving
entity’s voting power immediately after the transaction; or 

  

	 	(c)	a change in the composition of the Company’s board of directors, as a result of which fewer than a majority of the directors are incumbent directors. Incumbent directors shall mean directors who either
(A) were Company directors as of the date of this Agreement, or (B) are elected, or nominated for election, to the Company’s board of directors with the affirmative votes of at least a majority of the incumbent directors at the time
of such election or nomination, but shall not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of members to the Company’s board of directors.

 And provided further that in each of the foregoing cases, the Change in Control also meets all of the requirements of a
“change in the ownership of a corporation” within the meaning of Treasury Regulation § 1.409A- 3(i)(5)(v), a “change in the effective control of a corporation” within the meaning of Treasury Regulation § 1.409A-
3(i)(5)(vi) or a “a change in the ownership of a substantial portion of the corporation’s assets” within the meaning of Treasury Regulation § 1.409A-3(i)(5)(vii). 

 

	 	3.	“Code” shall mean the Internal Revenue Code of 1986, as amended. 

  

	 	4.	“Disability” shall mean a disability as determined under the Company’s long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists
at the time of disability, then a “disability” as defined Section 22(e)(3) of the Code. 

  

	 	5.	“Good Reason” shall mean one of the following events has occurred without your consent: 

  

	 	(a)	your annual base salary is decreased; 

  

	 	(b)	your principal place of employment is relocated to a place 35 or more miles away from one of the Company’s locations; or 

  

	 	(c)	the Company breaches the material terms of any employment agreement then in effect or you experience a material adverse change to your primary responsibilities or duties. 

And provided further that Good Reason shall not exist unless and until within 90 days after the event giving rise to Good Reason under (a), (b)
or (c) above has occurred, you deliver a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that you assert constitutes Good Reason under (a),
(b) or (c) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving your notice. To avoid doubt, the termination of your employment would become effective at the close
of business on the thirtieth day after the Company receives your termination notice, unless the Company cures or eliminates the event giving rise to Good Reason prior to such time. 

 

	 	6.	“Termination Date” shall mean the last day of your employment with the Company. 

  

	II.	Severance Benefits 

  

	 	1.	Severance shall be paid to you if your employment is terminated by the Company (except for termination for Cause or due to death or a Disability) or if you, of your own initiative, terminate your employment for Good
Reason (in accordance with the notice and cure provisions in this Agreement), provided that the termination of your employment also constitutes a “separation from service” as defined by Code Treasury Regulation § 1.409A-1(h). 

  
 Page 2 of 5 

	 	2.	In the event you are eligible for severance, the Company shall make a cash payment (the “Severance Payment”) to you in an amount equal to six months of your annual base salary (less applicable
withholdings) on a payroll basis (provided, however, that if you terminate your employment for Good Reason based on a reduction in your annual base salary, then the annual base salary to be used in calculating the Severance Payment shall be your
annual base salary in effect immediately prior to such reduction in annual base salary). If you are covered under the Company’s group medical and dental coverage as of the Termination Date, and if you are eligible to continue such coverage
pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company will reimburse the employer portion of the premium costs (consistent with the Company’s policy for active employees) of such
continuation coverage until the earlier of (i) the end of the sixth month following the Termination Date; or (ii) the date that you become eligible for coverage under another group health plan. 

 

	 	3.	The Severance Payment will only be made in exchange for a general release to be executed by you, which becomes enforceable and irrevocable within 60 days of your Termination Date, of all claims against the Company, its
subsidiaries, and its and their officers, directors and representatives, in a form satisfactory to the Company. The Severance Payment shall begin within ten days after the execution by you of the general release and expiration without revocation of
any applicable revocation periods under such general release, provided that, if the 60 day period during which the release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance
Payment shall be made in the second calendar year. 

  

	 	4.	You shall not be required to mitigate the amount of the Severance Payment or any other benefit provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit
provided for in this Agreement be reduced (except as provided in this Agreement) by any compensation earned by you as the result of other employment, by retirement benefits, or be offset against any amount claimed to be owed by you to the Company or
otherwise (except for any required withholding taxes); provided, that if the Company makes any other severance payments to you under any other program or agreement, such amounts shall be offset against the payments the Company is obligated to make
pursuant to this Agreement. 

  

	III.	Pro-Rated Bonus upon Change in Control 

 If,
within six (6) months of the effective date of a Change in Control, you are terminated without Cause or you resign for Good Reason, you will be entitled to the pro-rata portion of the annual bonus for the
year in which the termination of your employment occurs, based on the number of months of completed employment up to the Termination Date, payable no later than March 1 of the following year, in one
lump-sum amount (less required withholdings). 
  

	IV.	Miscellaneous. 

  

	 	1.	 Section 409A Compliance. The payments and benefits provided for in Section II of this Agreement constitute
an involuntary separation plan pursuant to Treas. Reg. § 1.409A-1(n), and thus is not “non-qualified deferred compensation” subject to Section 409A
of the Code. To the extent that any of the payments or benefits provided for in Section II are deemed to constitute non-qualified deferred compensation benefits subject to Section 409A of the Code,
however, the following interpretations apply: Any termination of your employment triggering payment of benefits under Section II must constitute a “separation from service” under Section 409A(a)(2) (A)(i) of the Code and Treasury
Regulation § 1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination of your employment does not constitute a separation of service under
Section 409A(a)(2)(A)(i) of the Code and Treasury Regulation § 1.409A-l (h) (as the result of further services that are reasonably anticipated to be provided by you to the Company or any of its
parents, subsidiaries or affiliates at the time your employment terminates), any benefits payable under Section II that constitute deferred compensation under Section 409A of the Code shall be delayed until after the date of a subsequent event
constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treasury Regulation § 1.409A-1(h). For purposes of

  
 Page 3 of 5 

	 	
clarification, this Section shall not cause any forfeiture of benefits on your part, but shall only act as a delay until such time as a “separation from service” occurs. Further, if you
are a “specified employee” (as that term is used in Section 409A of the Code and regulations and other guidance issued thereunder) on the date a separation from service becomes effective, any benefits payable under Section II that
constitute non-qualified deferred compensation under Section 409A of the Code shall be delayed until the earlier of (i) the business day following the
six-month anniversary of the date your separation from service becomes effective, and (ii) the date of your death, but only to the extent necessary to avoid such penalties under Section 409A of the
Code. On the earlier of (i) the business day following the six-month anniversary of the date your separation from service becomes effective, and (ii) your death, the Company shall pay you (or your
estate) in a lump sum the aggregate value of the non-qualified deferred compensation that the Company otherwise would have paid you prior to that date under Section II of this Agreement. It is intended that
each installment of the payments and benefits provided under Section II of this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to
accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code. 

  

	 	2.	Employee’s Obligations. Upon the termination of employment, you shall promptly deliver to the Company all property of the Company and all material documents, data and other items which may by in your
possession or under your control and which relate in a material way to the business or affairs of the Company or its subsidiaries, and no copies of any such documents or any part thereof shall be retained by you. Any post-employment obligations you
may have pursuant to separate agreements supplement but do not supersede this Agreement and shall survive as provided for in such separate agreements. 

  

	 	3.	Entire Agreement. This Agreement and any employment or confidentiality and non-competition and equity agreements previously executed by you covers the entire understanding
of the parties as to the subject matter hereof, superseding all prior understandings and agreements related hereto. No modification or amendment of the terms and conditions of this Agreement shall be effective unless in writing and signed by the
parties or their respective duly authorized agents. 

  

	 	4.	Governing Law. This Agreement shall be governed by the laws of the State of New York, without giving effect to any principles of conflicts of laws. 

 

	 	5.	Successors and Assigns. This Agreement may be assigned by the Company upon a sale, transfer or reorganization of the Company. Upon a Change in Control, the Company shall require the successor to assume the
Company’s rights and obligations under this Agreement. The Company’s failure to do so shall constitute a material breach of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their
successors, permitted assigns, legal representatives and heirs. 

  
 Page 4 of 5 

 Kindly indicate your acceptance of the foregoing by signing and dating this Agreement as noted
below, and returning one fully executed original to my attention. 
  

			
	Very truly yours,
	
	Melinta Therapeutics, Inc.
		
	By:	 	
                     
                    

  

	
	ACCEPTED AND AGREED:
	
	 

  

	JOHN TEMPERATO
	
	 2.9.2016

	DATE

  
 Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]